EML4 and neoplasm: Crizotinib is a tyrosine kinase inhibitor with demonstrated effectiveness against echinoderm microtubule-associated protein-like 4 (EML4)-ALK rearrangements as well as anti-tumour activity against biologically similar domains of ROS1 and another proto-oncogene receptor tyrosine kinase, MET [5, 6].